Rice Partnership LLC Has $488,000 Holdings in Bristol-Myers Squibb Co (NYSE:BMY)

Rice Partnership LLC decreased its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 14.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,234 shares of the biopharmaceutical company’s stock after selling 1,700 shares during the quarter. Rice Partnership LLC’s holdings in Bristol-Myers Squibb were worth $488,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of BMY. Capital Financial Planning LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $28,000. Financial Gravity Wealth Inc. bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $26,000. Well Done LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $30,000. Riverview Trust Co bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $33,000. Finally, Trust Department MB Financial Bank N A bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $32,000. Institutional investors and hedge funds own 77.65% of the company’s stock.

Shares of BMY stock opened at $47.63 on Thursday. The stock has a market capitalization of $76.67 billion, a PE ratio of 11.97, a PEG ratio of 2.19 and a beta of 0.74. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.93 and a quick ratio of 1.79. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.09 by $0.01. The company had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The firm’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.94 earnings per share. On average, equities research analysts anticipate that Bristol-Myers Squibb Co will post 4.18 earnings per share for the current fiscal year.

In other Bristol-Myers Squibb news, insider Karen Murphy Santiago sold 3,065 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the completion of the transaction, the insider now owns 3,066 shares in the company, valued at $145,818.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Theodore R. Samuels II bought 5,000 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were acquired at an average price of $47.29 per share, with a total value of $236,450.00. Following the transaction, the director now directly owns 27,000 shares of the company’s stock, valued at $1,276,830. The disclosure for this purchase can be found here. Corporate insiders own 0.12% of the company’s stock.

Several research analysts recently issued reports on BMY shares. BMO Capital Markets increased their target price on shares of Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Friday, February 22nd. ValuEngine lowered shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 4th. Goldman Sachs Group started coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, May 28th. They set a “buy” rating and a $54.00 target price on the stock. Finally, Argus lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 target price on the stock. in a research note on Monday, May 20th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $56.69.

WARNING: This piece of content was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2019/06/13/rice-partnership-llc-has-488000-holdings-in-bristol-myers-squibb-co-nysebmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: Investing strategies using the yield curve

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.